Mer­ri­mack CEO, CFO bow out, months af­ter last clin­i­cal drug fiz­zles

Richard Pe­ters Mer­ri­mack

Two months ago, Mer­ri­mack was forced to aban­don its last drug in clin­i­cal tri­als, af­ter an ear­ly-stage study showed that treat­ment with the drug, MM-310, was cu­mu­la­tive­ly tox­ic to pa­tients, de­spite tri­al pro­to­col amend­ments. On Mon­day, the ex-Sanofi ex­ec­u­tive the Cam­bridge, Mass­a­chu­setts-based com­pa­ny ush­ered in 2017 to re­vive its for­tunes de­part­ed.

In 2015, Mer­ri­mack $MACK se­cured FDA ap­proval for its pan­cre­at­ic can­cer drug — Onivyde, which had a dis­ap­point­ing de­but. It was sold to Ipsen in 2017, in par­al­lel to a re­struc­tur­ing, which cul­mi­nat­ed in a new CEO — Richard Pe­ters — a slim­mer work­force and three pipeline prospects: MM-141, MM-121 and MM-310. Each of these drugs has now been rel­e­gat­ed to the scrap heap.

Jean Franchi LinkedIn

In April, af­ter ax­ing MM-310, the com­pa­ny said it was cut­ting jobs, but did not spec­i­fy how many. It now has two pre­clin­i­cal drugs — MM-401 and MM-201 — left in its ar­se­nal. Last No­vem­ber, the com­pa­ny slashed its work­force by 60%, weeks af­ter dis­clos­ing MM-121, or serib­an­tum­ab, added to do­c­etax­el made no dif­fer­ence to pa­tients with non-small cell lung can­cer. This slash and burn was pre­ced­ed by an­oth­er flop in 2018. The com­pa­ny rid it­self of MM-141 af­ter it failed a Phase II com­bo study in pan­cre­at­ic can­cer.

On Mon­day, Mer­ri­mack said Pe­ters was leav­ing the com­pa­ny. He will re­ceive $743,746.21 — 12 months of his base salary — in sev­er­ance, a pro-rat­ed bonus of $294,891.15, and the com­pa­ny will con­tin­ue pay­ing a share of the pre­mi­um for Pe­ters’ health and den­tal in­sur­ance for a pe­ri­od of one year (un­less he changes his cov­er­age). Pe­ters on June 25 agreed to con­sult with Mer­ri­mack at a rate of $30,989.43 per month to as­sist with its re­port­ing oblig­a­tions and the ad­min­is­tra­tion of re­main­ing as­sets.

Gary Crock­er Crock­er Ven­tures

Apart from Pe­ters, CFO Jean Franchi and board chair­man Gary Crock­er are al­so de­part­ing. Franchi gets $415,002.70 in sev­er­ance, a pro-rat­ed bonus of $77,544.30, a share paid for health and den­tal in­sur­ance, and con­sult­ing fees of $17,291.78 per month.

As of March 31, Mer­ri­mack had an ac­cu­mu­lat­ed deficit of $533.7 mil­lion; cash, cash equiv­a­lents and mar­ketable se­cu­ri­ties of $58.5 mil­lion; and said it ex­pects to con­tin­ue to gen­er­ate op­er­at­ing loss­es in the fore­see­able fu­ture in a fil­ing post­ed in May.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Fireside chat between Hal Barron and John Carroll, UKBIO19

It’s time we talked about bio­phar­ma — live in Lon­don next week

Zoom can only go so far. And I think at this stage, we’ve all tested the limits of staying in touch — virtually. So I’m particularly happy now that we’ve revved up the travel machine to point myself to London for the first time in several years.

Whatever events we have lined up, we’ve always built in plenty of opportunities for all of us to get together and talk. For London, live, I plan to be right out front, meeting with and chatting with the small crowd of biopharma people we are hosting on October 12 at Silicon Valley Bank’s London headquarters. And there’s a lengthy mixer at the end I’m most looking forward to, with several networking openings between sessions.

Car­olyn Bertozzi (Illustration: Assistant editor Kathy Wong for Endpoints News)

Car­olyn Bertozzi, re­peat biotech founder and launch­er of a field, shares in chem­istry No­bel win

Carolyn Bertozzi, predicted by some to become a Nobel laureate, clinched one of the world’s top awards in the wee hours of Wednesday, winning the Nobel Prize in Chemistry alongside a repeat winner and a Copenhagen researcher.

The Stanford professor, Morten Meldal of University of Copenhagen and 2001-awardee K. Barry Sharpless of Scripps shared the prize equally. The Nobel is sometimes split in quarters and/or halves.

Pfizer and BioNTech's original Marvel comic book links evolving Covid vaccine science to Avengers' evolving villain-fighting tools.(Source: Pfizer LinkedIn post)

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

Pfizer and BioNTech are collaborating with Marvel to celebrate “everyday” people getting Covid-19 vaccines in a custom comic book.

In the “Everyday Heroes” digital comic book, an evolving Ultron, one of the Avengers’ leading villains, is defeated by Captain America, Ironman and others. The plotline and history of Ultron is explained by a grandfather who is waiting with his family at a clinic for Covid-19 vaccinations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.

Due to unresolved supply issues and manufacturing woes, Takeda said it will cut its losses and discontinue its hypoparathyroidism drug, known as Natpara (parathyroid hormone), halting all manufacturing of the drug by the end of 2024, but the entire inventory will be available until depleted or expired, a company spokesperson said via email.

Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry

It looks like Eli Lilly and Teva Pharmaceuticals are going to trial.

A federal appeals court on Monday refused to invalidate three of Teva’s patents for its migraine treatment Ajovy, while also declining to issue a summary judgment in favor of either company, which would effectively end the case without a full trial.

Teva filed suit against Lilly back in 2018, alleging that the company infringed upon nine patents with its rival migraine drug Emgality. The rival drugs were both approved in September 2018 for the preventative treatment of migraine, and are designed to block calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Rep. Vern Buchanan (R-FL) (Bill Clark/CQ Roll Call via AP Images)

Af­ter cov­er­age re­stric­tions for Alzheimer's drugs, bi­par­ti­san House bill would force CMS to re­view drugs in­di­vid­u­al­ly

When Biogen’s controversial Alzheimer’s drug Aduhelm was hit with a national decision from CMS that restricted coverage to only randomized trials, practically guaranteeing a commercial flop in the near term, questions surfaced over why CMS also included all amyloid-targeted monoclonal antibodies for Alzheimer’s disease.

With Eisai and Biogen’s second Alzheimer’s drug, lecanemab, now showing it can slow the rate of cognitive decline versus placebo, lining up for a likely full approval next spring, the question now turns to whether that data, which is being presented at the Clinical Trials on Alzheimer’s Congress in San Francisco in late November, will be enough for CMS when it asks, “Does the anti-amyloid mAb meaningfully improve health outcomes (i.e., slow the decline of cognition and function) for patients in broad community practice?”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

FDA+ roundup: Ad­comm date set for Cy­to­ki­net­ics heart drug; New gener­ic drug guid­ance to re­duce fa­cil­i­ty de­lays

The FDA on Wednesday set Dec. 13 as the day that its Cardiovascular and Renal Drugs Advisory Committee will review Cytokinetics’ potential heart drug, meaning regulators aren’t likely to meet the Nov. 30 PDUFA date that was previously set.

The drug, known as omecamtiv mecarbil, read out its first Phase III in November 2020, hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as the key to breaking into the market, failing to significantly differ in reducing cardiovascular death from placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.